TRexBio: $50 Million Raised To Advance Tissue-Targeted Treg Immunology Pipeline
By Amit Chowdhry ● Jan 28, 2026
TRex Bio, a clinical stage biotechnology company focused on precision immunoregulatory medicines derived from tissue regulatory T cell biology, announced it closed an oversubscribed $50 million financing to support clinical and preclinical pipeline development and expand work on its proprietary Deep Biology Platform. The round brought in new investors Janus Henderson Investors, Balyasny Asset Management L.P., and Affinity Asset Advisors, alongside existing backers Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc, Pfizer Ventures, Polaris Partners, and SV Health Investors.